Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

Presentation ESC 2016

ANTARCTIC: Assessment of a Normal vs Tailored Dose of Prasugrel After Stenting in 75 yo Patients to Reduce the Composite of Bleeding, Stent Thrombosis and Ischemic Complications

Presenter: Gilles Montalescot

August 28, 2016

Presentation ESC 2015

Aldosterone Lethal Effects Blockade in Acute Myocardial Infarction Treated With or Without Reperfusion to Improve Outcome and Survival at Six Months Follow-Up

Presenter: Gilles Montalescot

August 30, 2015

Presentation

Early Eplerenone Treatment in Patients with Acute STEMI Without HF: The REMINDER Study

Presenter: 140896|Gilles Montalescot

May 05, 2014

Presentation

High On-Treatment Platelet Reactivity as a Risk Factor for Secondary Prevention After Stenting

Presenter: Gilles Montalescot

April 11, 2014

Presentation TCT 2013

Self-Expanding Stents Provide a Real Benefit During STEMI Intervention!

Presenter: Gilles Montalescot

October 31, 2013

Presentation TCT 2013

Prasugrel Preloading in NSTEMI: ACCOAST Recap

Presenter: Gilles Montalescot

October 31, 2013

Presentation TCT 2013

BRIDGE Recap

Presenter: Gilles Montalescot

October 31, 2013

Presentation TCT 2013

TCT-123. Preliminary safety and efficacy results from the REALISE trial: REnAL denervatIon by ultraSound transcatheter Emission

Presenter: Gilles Montalescot

October 30, 2013

Presentation TCT 2013

Yes! The European Union Has It Right

Presenter: Gilles Montalescot

October 28, 2013

Presentation TCT 2013

Aldosterone Antagonism After MI

Presenter: Gilles Montalescot

October 27, 2013

Presentation ACC 2013

A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardIal InfarctiON in Real Life: APPOSITION III Study

Presenter: Gilles Montalescot

March 08, 2013

Presentation TCT 2012

For: Delaying Is of No Benefit and Only Increases Health Costs: Why Wait?!

Presenter: Gilles Montalescot

October 25, 2012

$Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!$

Presentation TCT 2012

Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!

Presenter: Gilles Montalescot

October 25, 2012

Presentation TCT 2012

Use of the REG1 Anticoagulation System During PCI May Improve Bleeding and Ischemic Complications Compared with Heparin: A PCI Substudy from the Phase 2B RADAR Trial

Presenter: Thomas J. Povsic, John P. Vavalle, Laura H. Aberle, Steven L. Zelenkofske, Roxana Mehran, Mauricio G. Cohen, Christopher E. Buller, Jan H. Cornel, Jaroslaw D. Kasprzak, Gilles Montalescot, Peter Fail, Ian J. Sarembock, John H. Alexander

January 03, 2012

Advertisement

ANTARCTIC: Assessment of a Normal vs Tailored Dose of Prasugrel After Stenting in 75 yo Patients to Reduce the Composite of Bleeding, Stent Thrombosis and Ischemic Complications

Aldosterone Lethal Effects Blockade in Acute Myocardial Infarction Treated With or Without Reperfusion to Improve Outcome and Survival at Six Months Follow-Up

Early Eplerenone Treatment in Patients with Acute STEMI Without HF: The REMINDER Study

High On-Treatment Platelet Reactivity as a Risk Factor for Secondary Prevention After Stenting

Self-Expanding Stents Provide a Real Benefit During STEMI Intervention!

Prasugrel Preloading in NSTEMI: ACCOAST Recap

BRIDGE Recap

TCT-123. Preliminary safety and efficacy results from the REALISE trial: REnAL denervatIon by ultraSound transcatheter Emission

Yes! The European Union Has It Right

Aldosterone Antagonism After MI

A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardIal InfarctiON in Real Life: APPOSITION III Study

For: Delaying Is of No Benefit and Only Increases Health Costs: Why Wait?!

Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!

Use of the REG1 Anticoagulation System During PCI May Improve Bleeding and Ischemic Complications Compared with Heparin: A PCI Substudy from the Phase 2B RADAR Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content